Vidharshana Konda Sridharan

Background: Fetal Alcohol Spectrum Disorders (FASDs) are lifelong physical, behavioral, and cognitive impairments caused by prenatal alcohol exposure (PAE), affecting 1-5% of U.S. school-aged children.^1,2 The current diagnostic standard relies on postnatal observation of facial dysmorphology, growth deficits, and neurobehavioral impairment, which often do not become apparent until school age.² Non-dysmorphic cases are frequently diagnosed late or not at all, resulting in missed opportunities for early intervention during critical windows of neural plasticity.² The underlying molecular damage, however, begins within days of conception. Prenatal alcohol exposure disrupts genome-wide DNA methylation reprogramming in the pre-implantation embryo, potentially leaving detectable epigenetic marks across multiple developmental stages. Whether these molecular changes can serve as early biomarkers warrants further study.

Objective: This narrative review examines whether molecular biomarkers of PAE can be identified across four developmental windows (early embryogenesis, placental development, third-trimester fetal circulation, and early infancy) prior to the onset of deficits associated with FASDs.

Search Methods: An online search was conducted in PubMed using the following MeSH terms: “fetal alcohol spectrum disorders,” “prenatal alcohol exposure,” “epigenetics,” “DNA methylation,” “differentially methylated regions,” “placenta,” “microRNA,” “biomarkers,” and “cerebroplacental ratio.”

Results: Preclinical mouse models and human cohort studies demonstrated persistent epigenetic and physiologic alterations associated with PAE across multiple developmental stages.^1-6 Binge-level alcohol exposure during the preimplantation period produced widespread DNA hypomethylation in embryonic forebrain tissue, including in morphologically normal embryos.³ Placental analyses demonstrated persistent sex-specific methylation abnormalities, with male fetuses exhibiting greater disruption of imprinted growth-regulating genes and significant reductions in fetal growth.⁴ Maternal methyl-donor supplementation partially reduced PAE-associated methylation abnormalities, supporting a potentially modifiable early developmental window.⁵ In a human pregnancy cohort, 18% of PAE pregnancies demonstrated cerebroplacental ratios below the 5th percentile compared with 2% of controls on third-trimester Doppler ultrasound.¹ In a separate infant cohort, alcohol-exposed infants demonstrated distinct circulating microRNA profiles at both 2 weeks and 6.5 months of age, with several altered miRNAs correlating with later cognitive outcomes.⁶ Across studies, male fetuses consistently demonstrated greater molecular and physiologic vulnerability, supporting sex-specific mechanisms of injury.^1,3,4

Conclusion: These five studies identify four sequential windows in which molecular evidence of PAE can be detected before clinical symptoms appear: (1) embryonic DNA methylation errors within days of conception³; (2) sex-specific placental epigenetic disruptions persisting to late gestation⁴; (3) impaired fetal blood flow detectable by Doppler ultrasound in the third trimester¹; and (4) circulating miRNA signatures at two weeks correlating with cognitive outcomes at 6.5 months.⁶ Male fetuses showed greater methylation disruption and growth restriction; females demonstrated distinct compensatory responses.^1,3,4 Preclinical methyl-donor supplementation, including folate- and choline-enriched diets, partially reduced PAE-associated methylation abnormalities, suggesting targeted nutritional interventions may lessen downstream molecular effects.⁵ Together, these findings support a clinically feasible screening cascade: PAE disclosure could trigger Doppler monitoring, folate/choline supplementation, and a neonatal miRNA blood panel enabling early developmental services referral. The primary limitation is that no single study tracks all four biomarker windows within one cohort. Future longitudinal research is needed to validate this proposed screening pathway.

Works Cited

1. Steane SE, Edwards C, Cavanagh E, et al. Prenatal alcohol exposure is associated with altered feto-placental blood flow and sex-specific placental changes. JCI Insight. 2025;10(3):e186096. doi:10.1172/jci.insight.186096
2. Mattson SN, Bernes GA, Doyle LR. Fetal alcohol spectrum disorders: a review of the neurobehavioral deficits associated with prenatal alcohol exposure. Alcohol Clin Exp Res. 2019;43(6):1046-1062. doi:10.1111/acer.14040
3. Legault LM, Paquette AG, Lussier AA, et al. Pre-implantation alcohol exposure induces lasting sex-specific DNA methylation programming errors in the developing forebrain. Clin Epigenetics. 2021;13(1):164. doi:10.1186/s13148-021-01151-0
4. Legault LM, Dupas T, Breton-Larrivee M, et al. Sex-specific DNA methylation and gene expression changes in mouse placentas after early preimplantation alcohol exposure. Environ Int. 2024;192:109014. doi:10.1016/j.envint.2024.109014
5. Bestry M, Larcombe AN, Kresoje N, et al. Early moderate prenatal alcohol exposure and maternal diet impact offspring DNA methylation across species. 2024;12:RP92135. doi:10.7554/eLife.92135
6. Mahnke AH, Sideridis GD, Salem NA, et al. Infant circulating microRNAs as biomarkers of effect in fetal alcohol spectrum disorders. Sci Rep. 2021;11(1):1429. doi:10.1038/s41598-020-80734-y